In a notable development in the ongoing IP dispute between pharmaceutical giants Mylan and Takeda Pharmaceuticals USA Inc., a Delaware federal judge sided with Mylan on a breach of contract claim regarding Takeda’s gout drug Colcrys. The judge concurred with Mylan’s interpretation of an earlier settlement agreement.
Further details of the ruling are yet to emerge, offering an intriguing twist in the contentious battle over Intellectual Property rights in the pharmaceutical industry.